MMIT Reality Check on Epilepsy (Jan 2021)

According to our recent payer coverage analysis for epilepsy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for epilepsy treatments shows that under the pharmacy benefit, almost 39% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In June 2020, the FDA approved Zogenix, Inc.’s Fintepla (fenfluramine) to treat seizures associated with Dravet syndrome in people at least 2 years old. The price for a 30 mL bottle is $1,278.

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/12/wordpress-featured-image-reality-check-ovarian-cancer.jpg
December 3

MMIT Reality Check on Ovarian Cancer

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image_Diabetes.jpg
November 24

MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo)

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/11/wordpress-featured-image-reality-check-colorectal-cancer.jpg
November 19

MMIT Reality Check on Colorectal Cancer

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today